Propel Bio Management LLC Takes Position in SAB Biotherapeutics, Inc. $SABS

Propel Bio Management LLC acquired a new stake in SAB Biotherapeutics, Inc. (NASDAQ:SABS) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 652,881 shares of the company’s stock, valued at approximately $2,442,000. SAB Biotherapeutics comprises approximately 2.1% of Propel Bio Management LLC’s investment portfolio, making the stock its 14th largest holding.

A number of other hedge funds and other institutional investors also recently made changes to their positions in SABS. ADAR1 Capital Management LLC acquired a new stake in shares of SAB Biotherapeutics in the third quarter valued at approximately $30,000. Dimensional Fund Advisors LP acquired a new stake in shares of SAB Biotherapeutics in the third quarter valued at approximately $32,000. State of Wyoming acquired a new stake in shares of SAB Biotherapeutics in the fourth quarter valued at approximately $34,000. Virtu Financial LLC acquired a new stake in shares of SAB Biotherapeutics in the third quarter valued at approximately $40,000. Finally, Goldman Sachs Group Inc. raised its holdings in shares of SAB Biotherapeutics by 357.6% in the fourth quarter. Goldman Sachs Group Inc. now owns 51,348 shares of the company’s stock valued at $192,000 after purchasing an additional 40,127 shares during the last quarter. 7.82% of the stock is currently owned by institutional investors and hedge funds.

SAB Biotherapeutics Trading Down 2.6%

Shares of SAB Biotherapeutics stock opened at $3.38 on Friday. The firm has a 50-day moving average of $3.75 and a 200-day moving average of $3.87. The stock has a market cap of $258.43 million, a PE ratio of -1.60 and a beta of 0.54. SAB Biotherapeutics, Inc. has a 52-week low of $1.60 and a 52-week high of $6.60. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.45 and a current ratio of 11.45.

SAB Biotherapeutics (NASDAQ:SABS) last announced its earnings results on Tuesday, May 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.15). As a group, sell-side analysts forecast that SAB Biotherapeutics, Inc. will post -1.19 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently weighed in on SABS. Chardan Capital raised their target price on shares of SAB Biotherapeutics from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday, March 11th. HC Wainwright raised their target price on shares of SAB Biotherapeutics from $7.00 to $10.00 and gave the company a “buy” rating in a research note on Tuesday, May 12th. Weiss Ratings reissued a “sell (d+)” rating on shares of SAB Biotherapeutics in a research note on Friday, April 10th. Wall Street Zen cut shares of SAB Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 14th. Finally, Citigroup began coverage on shares of SAB Biotherapeutics in a research note on Friday, May 22nd. They issued a “buy” rating and a $11.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, SAB Biotherapeutics has a consensus rating of “Moderate Buy” and an average price target of $11.00.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.